Tamoxifen-stimulated growth of breast cancer due to p21 loss

Tamoxifen is widely used for the treatment of hormonally responsive breast cancers. However, some resistant breast cancers develop a growth proliferative response to this drug, as evidenced by tumor regression upon its withdrawal. To elucidate the molecular mediators of this paradox, tissue samples from a patient with tamoxifen-stimulated breast cancer were analyzed. These studies revealed that loss of the cyclin-dependent kinase inhibitor p21 was associated with a tamoxifen growth-inducing phenotype. Immortalized human breast epithelial cells with somatic deletion of the p21 gene were then generated and displayed a growth proliferative response to tamoxifen, whereas p21 wild-type cells demonstrated growth inhibition upon tamoxifen exposure. Mutational and biochemical analyses revealed that loss of p21's cyclin-dependent kinase inhibitory property results in hyperphosphorylation of estrogen receptor-α, with subsequent increased gene expression of estrogen receptor-regulated genes. These data reveal a previously uncharacterized molecular mechanism of tamoxifen resistance and have potential clinical implications for the management of tamoxifen-resistant breast cancers.

[1]  L. Hengst,et al.  p27 Phosphorylation by Src Regulates Inhibition of Cyclin E-Cdk2 , 2007, Cell.

[2]  G. Parmigiani,et al.  The Consensus Coding Sequences of Human Breast and Colorectal Cancers , 2006, Science.

[3]  A. Weeraratna,et al.  Interleukin-1 alpha mediates the growth proliferative effects of transforming growth factor-beta in p21 null MCF-10A human mammary epithelial cells , 2006, Oncogene.

[4]  Rakesh Kumar,et al.  Nuclear p21-activated kinase 1 in breast cancer packs off tamoxifen sensitivity. , 2006, Cancer research.

[5]  M. Salto‐Tellez,et al.  Mutational hotspot in Exon 20 of PIK3CA in breast cancer among singapore chinese , 2006, Cancer biology & therapy.

[6]  B. Park,et al.  Physiologic estrogen receptor alpha signaling in non-tumorigenic human mammary epithelial cells , 2006, Breast Cancer Research and Treatment.

[7]  Z. Duan,et al.  Gfi1 Coordinates Epigenetic Repression of p21Cip/WAF1 by Recruitment of Histone Lysine Methyltransferase G9a and Histone Deacetylase 1 , 2005, Molecular and Cellular Biology.

[8]  Simak Ali,et al.  ICI182,780 Induces p21Waf1 Gene Transcription through Releasing Histone Deacetylase 1 and Estrogen Receptor α from Sp1 Sites to Induce Cell Cycle Arrest in MCF-7 Breast Cancer Cell Line* , 2005, Journal of Biological Chemistry.

[9]  R. Schiff,et al.  Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. , 2004, Journal of the National Cancer Institute.

[10]  Yong Liao,et al.  Phosphorylation/Cytoplasmic Localization of p21Cip1/WAF1 Is Associated with HER2/neu Overexpression and Provides a Novel Combination Predictor for Poor Prognosis in Breast Cancer Patients , 2004, Clinical Cancer Research.

[11]  A. Floore,et al.  Tamoxifen resistance by a conformational arrest of the estrogen receptor alpha after PKA activation in breast cancer. , 2004, Cancer cell.

[12]  Hiroyuki Konishi,et al.  The PIK3CA gene is mutated with high frequency in human breast cancers , 2004, Cancer biology & therapy.

[13]  P. Argani,et al.  p21 (WAF1/CIP1) Mediates the Growth Response to TGF-b in Human Epithelial Cells , 2004, Cancer biology & therapy.

[14]  M. Dosik,et al.  Raloxifene Rebound Regression , 2004, Cancer investigation.

[15]  A. Harris,et al.  Cytoplasmic p21WAF1/CIP1 expression is correlated with HER-2/ neu in breast cancer and is an independent predictor of prognosis , 2003, Breast Cancer Research.

[16]  Julia Tischler,et al.  The Tumor Suppressor p53 and Histone Deacetylase 1 Are Antagonistic Regulators of the Cyclin-Dependent Kinase Inhibitor p21/WAF1/CIP1 Gene , 2003, Molecular and Cellular Biology.

[17]  S. Hilsenbeck,et al.  Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. , 2003, Journal of the National Cancer Institute.

[18]  L. Hartmann,et al.  Selective estrogen-receptor modulators -- mechanisms of action and application to clinical practice. , 2003, The New England journal of medicine.

[19]  E. Gabrielson,et al.  Variable levels of chromosomal instability and mitotic spindle checkpoint defects in breast cancer. , 2002, The American journal of pathology.

[20]  J. A. Castillejo,et al.  5' CpG island hypermethylation is associated with transcriptional silencing of the p21(CIP1/WAF1/SDI1) gene and confers poor prognosis in acute lymphoblastic leukemia. , 2002, Blood.

[21]  Myles Brown,et al.  Molecular Determinants for the Tissue Specificity of SERMs , 2002, Science.

[22]  J. Robertson.  Faslodex (ICI 182, 780), a novel estrogen receptor downregulator—future possibilities in breast cancer , 2001, The Journal of Steroid Biochemistry and Molecular Biology.

[23]  J. Bartek,et al.  p21/WAF1/Cip1 expression in invasive ductal breast carcinoma: relationship to p53, proliferation rate, and survival at 5 years , 2001, Virchows Archiv.

[24]  M. Hung,et al.  Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells , 2001, Nature Cell Biology.

[25]  P. Marks,et al.  Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[26]  J. Slingerland,et al.  Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[27]  Osborne Ck,et al.  Tamoxifen in the Treatment of Breast Cancer , 1998 .

[28]  Mike Clarke,et al.  Tamoxifen for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[29]  Bernard Ducommun,et al.  p21 binding to PCNA causes G1 and G2 cell cycle arrest in p53-deficient cells , 1998, Oncogene.

[30]  M. Garabedian,et al.  Regulation of estrogen receptor transcriptional enhancement by the cyclin A/Cdk2 complex. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[31]  R. Weinberg,et al.  Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution , 1997, Molecular and cellular biology.

[32]  G. Hannon,et al.  Functional Analysis of a p21WAF1,CIP1,SDI1 Mutant (Arg94 → Trp) Identified in a Human Breast Carcinoma , 1996, The Journal of Biological Chemistry.

[33]  P. Briand,et al.  Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1. , 1994, Cancer research.

[34]  J. Trent,et al.  WAF1, a potential mediator of p53 tumor suppression , 1993, Cell.

[35]  A. Howell,et al.  Response after withdrawal of tamoxifen and progestogens in advanced breast cancer. , 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

[36]  S. Ho,et al.  Site-directed mutagenesis by overlap extension using the polymerase chain reaction. , 1989, Gene.

[37]  J. Aisner,et al.  Tamoxifen withdrawal response. Report of a case. , 1989, Archives of internal medicine.

[38]  S. Legha,et al.  Tamoxifen in the treatment of breast cancer. , 1988, Annals of internal medicine.

[39]  P. Canney,et al.  CLINICAL SIGNIFICANCE OF TAMOXIFEN WITHDRAWAL RESPONSE , 1987, The Lancet.

[40]  G. Hortobagyi,et al.  Response of metastatic breast cancer to tamoxifen withdrawal: Report of a case , 1983, Journal of surgical oncology.

[41]  P. Band,et al.  Tamoxifen-induced tumor stimulation and withdrawal response. , 1979, Cancer treatment reports.

[42]  G. Duggin,et al.  CALCIUM BALANCE IN PREGNANCY , 1974, The Lancet.

[43]  M. Williamson,et al.  p21WAF1/CIP1 gene is inactivated in metastatic prostatic cancer cell lines by promoter methylation , 2005, Prostate Cancer and Prostatic Diseases.

[44]  D. Wolf,et al.  Characterization of tamoxifen stimulated MCF-7 tumor variants grown in athymic mice , 2004, Breast Cancer Research and Treatment.

[45]  J. A. Castillejo,et al.  CpG island hypermethylation is associated with transcriptional silencing of the p 21 CIP 1 / WAF 1 / SDI 1 gene and confers poor prognosis in acute lymphoblastic leukemia , 2002 .